So this was what ML was alerting as. Down the road...
Press Release Source: Genentech
Genentech and ABC2 Agree to Collaborate on Brain Cancer Clinical Trial
Thursday May 8, 9:03 am ET
BURLINGAME, Calif. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--May 8, 2003--Accelerate Brain Cancer Cure (ABC(2)), a non-profit association dedicated to accelerating therapies leading to a cure for brain cancer, and Genentech, Inc. (NYSE:DNA - News), today announced that they have agreed on terms under which the ABC(2) Clinical Network will be used for a clinical trial with Tarceva(TM) (erlotinib HCl) in glioblastoma multiforme (GBM), an advanced form of brain cancer. Tarceva is designed to inhibit the tyrosine kinase activity of the HER1/EGFR signaling pathway inside the cell, which may block tumor cell growth. Tarceva is currently being studied as an oral tablet by an alliance of Genentech, OSI Pharmaceuticals (Nasdaq:OSIP - News), and Roche (SWX:Zurich).
"Based on encouraging results of a Phase I study with Tarceva in glioma, we recently made the decision to initiate a Phase II study," said Gwen Fyfe, M.D., Genentech's vice president of Clinical Hematology/ Oncology. "We welcome the opportunity to work with the ABC(2) Clinical Network, which includes many preeminent neuro-oncology centers in the United States."
The ABC(2) Clinical Network provides guidance and counsel to ABC(2) and various sponsors of therapeutics in the design and execution of early stage, molecularly targeted clinical trials for adult GBM. Charter members of the network include four leading neuro-oncology centers: University of California, San Francisco; University of California, Los Angeles; Duke University; and M.D. Anderson Cancer Center. The network's focus is to understand and exploit specific abnormalities in individual patients through science-driven trials and to locate appropriate patients for clinical trials. In addition, a key component of the ABC(2) Clinical Network is the acquisition and testing of tumor tissue to understand the effects of treatment in specific patients, and to raise awareness of the need for available tissue samples among patients. <snip> |
